Brokerages expect BioScrip Inc (NASDAQ:BIOS) to announce earnings of ($0.12) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioScrip’s earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.09). BioScrip also posted earnings per share of ($0.12) in the same quarter last year. The company is scheduled to issue its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that BioScrip will report full-year earnings of ($0.25) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.14). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.21) to ($0.17). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for BioScrip.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.11). The company had revenue of $183.57 million for the quarter, compared to analysts’ expectations of $188.39 million. During the same period in the previous year, the company earned ($0.03) EPS. The firm’s quarterly revenue was up .5% compared to the same quarter last year.
A number of research analysts recently issued reports on the company. TheStreet cut BioScrip from a “c-” rating to a “d” rating in a report on Wednesday, April 3rd. BidaskClub cut BioScrip from a “buy” rating to a “hold” rating in a research note on Thursday, January 17th. Canaccord Genuity dropped their price objective on BioScrip from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Monday, March 18th. Zacks Investment Research lowered BioScrip from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. Finally, Stephens lowered BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price objective on the stock. in a report on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. BioScrip currently has an average rating of “Hold” and a consensus price target of $4.70.
Institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC raised its stake in BioScrip by 13.7% in the fourth quarter. Squarepoint Ops LLC now owns 52,389 shares of the company’s stock worth $187,000 after buying an additional 6,303 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of BioScrip by 60.6% in the fourth quarter. Virtu Financial LLC now owns 18,208 shares of the company’s stock valued at $65,000 after purchasing an additional 6,868 shares during the period. Maven Securities LTD acquired a new stake in shares of BioScrip in the fourth quarter valued at about $45,000. Caxton Associates LP acquired a new position in shares of BioScrip in the fourth quarter valued at approximately $52,000. Finally, Royce & Associates LP grew its holdings in BioScrip by 1.1% in the fourth quarter. Royce & Associates LP now owns 2,228,500 shares of the company’s stock valued at $7,956,000 after purchasing an additional 24,500 shares during the period. Institutional investors and hedge funds own 82.40% of the company’s stock.
BIOS stock traded down $0.01 during midday trading on Friday, hitting $1.76. The stock had a trading volume of 39,119 shares, compared to its average volume of 2,054,197. The stock has a market cap of $225.54 million, a P/E ratio of -3.58 and a beta of 0.69. BioScrip has a 52 week low of $1.69 and a 52 week high of $4.14.
BioScrip Company Profile
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.